{"id":"W2162854541","doi":"10.1016/s1470-2045(12)70508-9","title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Adjuvant; Medicine; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer; Trastuzumab; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003177237,0.0002503099,0.001668479,0.00007509331,0.0001657165,0.00002378903,0.0002819558,0.0001686384,0.001134105],"category_scores_gemma":[0.0002871694,0.0001369353,0.0001380364,0.0001882513,0.0003556342,0.00008770498,0.00004865575,0.0005265016,0.00004688924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000845329,"about_ca_system_score_gemma":0.0009698917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005403818,"about_ca_topic_score_gemma":0.0002145313,"domain_scores_codex":[0.99697,0.0006431795,0.0004200011,0.0003004392,0.000399548,0.001266848],"domain_scores_gemma":[0.9970058,0.001611545,0.0002516402,0.0004909057,0.0002630086,0.0003771322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9552616,0.000985699,0.001464689,0.0001070921,0.0006058398,0.00003696105,0.0036696,0.000003283084,0.0006458953,0.0002260704,0.008144134,0.02884906],"study_design_scores_gemma":[0.8459197,0.009523089,0.002384525,0.00007631385,0.0002356825,0.00011448,0.000609161,0.00008333527,0.0003413891,0.00003601993,0.1405039,0.0001724331],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9583134,0.0008995922,0.0001971206,0.01643867,0.0007040156,0.01082615,0.0007177028,0.00008856259,0.01181478],"genre_scores_gemma":[0.973401,0.000569312,0.000259428,0.002606139,0.006267573,0.0125008,0.00002502146,0.00006587848,0.004304867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1323597,"threshold_uncertainty_score":0.999779,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07012591633160038,"score_gpt":0.4331264314935411,"score_spread":0.3630005151619408,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}